Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090673 | 0.97 | FFAR3 (0.38) | CYP2C19FFAR3AKR1C1LMNAOPRM1 | |
| Hydrochloric Acid SCHEMBL6601346 | 0.95 | FFAR3 (0.36) | CYP2C19FFAR3AKR1C1LMNAOPRM1 | |
| SCHEMBL22533638 | 0.92 | FFAR3 (0.38) | CYP2C19FFAR3AKR1C1OPRM1OPRL1 | |
| SCHEMBL643056 | 0.87 | — | — | |
| SCHEMBL23832502 | 0.83 | CYP2C19 (0.37) | CYP2C19FFAR3AKR1C1LMNAKMT2A | |
| SCHEMBL12861247 | 0.80 | LMNA (0.35) | LMNAOPRM1OPRL1KMT2AMEN1 | |
| SCHEMBL2875860 | 0.78 | LMNA (0.36) | CYP2C19LMNAOPRM1KMT2AMEN1 | |
| SCHEMBL3667122 | 0.78 | MEN1 (0.34) | CYP2C19FFAR3KMT2AMEN1POLB | |
| SCHEMBL3949935 | 0.78 | CYP2C19 (0.33) | CYP2C19FFAR3KMT2AMEN1POLB | |
| SCHEMBL20599700 | 0.76 | OPRM1 (0.40) | CYP2C19FFAR3OPRM1OPRL1FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | WANG JIANMIN | 2010-07-22 | — | — | US | claimed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | claimed |
| EP-3724192-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | Richter Gedeon Nyrt. (HU) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019116324-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2019-06-20 | — | — | WO | disclosed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | WANG JIANMIN | 2010-07-22 | — | — | US | disclosed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7662786-B2 | oligopeptides; anticarcinogenic agent; good water solubility and cost effective; , B, D, E, F, G and K are alpha -amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as,an amino group, an N-substituted amino group, a beta -hydroxylamino group, an alkoxy group | ABBOTT GMBH & CO. KG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | disclosed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | disclosed |
| EP-0920549-B1 | MANUFACTURING METHOD AND NONWOVEN WEB | BKI HOLDING CORP (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0991658-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-12 | — | — | EP | disclosed |
| EP-0920549-A1 | MANUFACTURING METHOD AND NONWOVEN WEB | UPM-Kymmene Oy (FI) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998007914-A1 | MANUFACTURING METHOD AND NONWOVEN WEB | UPM-KYMMENE OY (FI) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | CYP2C19 1236/4885FFAR3 720/4885AKR1C1 94/4885 |
| US-20100184814-A1 | Ester Derivatives of Losartan, Methods for Their Preparation, and Uses Thereof | REN, ACE, AGTR1 | CYP2C19 47/4885FFAR3 148/4885AKR1C1 65/4885 |
| US-20060270606-A1 | Dolastatin 15 derivatives | DDOST, DBI, DAO | CYP2C19 1236/4885FFAR3 720/4885AKR1C1 94/4885 |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | CYP2C19 1236/4885FFAR3 720/4885AKR1C1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.